Two NIH Institutes Will Fund New Synchrotron Beamlines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

BETHESDA, Maryland-Two National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.

BETHESDA, Maryland—Two National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.

The National Cancer Institute and the National Institute of General Medical Sciences expect the $23 million project to be fully operational in about 3 years. The three beamlines will be added to the new Advanced Proton Source at Argonne National Laboratory in Illinois.

Articles in this issue
ODAC Sends Mixed Message on New Gliadel Wafer Indication
ONCC Certification Test Results Are Announced
Rituximab Ups Survival in Aggressive and Indolent NHL
Topotecan Used in Aggressive Front-Line Therapy for SCLC
Depsipeptide Shows Activity in T-Cell Lymphoma
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
FDA and VA Plan Joint AIDS Study
Breast Conservation Increases With On-Site Radiation Unit
Washington State Hikes Cigarette Tax
Moffitt’s Diet Guidelines for Immunocompromised Patients
AMA Approves New CPT Code for Serum HER-2 Test
NCI Formalizes Role of Advocates
Better Prognosis for Outer Quadrant Breast Cancers
Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content
Additionally, histologic subtype had a significant prognostic influence on PFS, as adenocarcinoma had doubled the risk of recurrence compared with squamous carcinoma, which had an equivalent risk of recurrence compared with adenosquamous carcinoma.

Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer

Tim Cortese
October 22nd 2025
Article

Patients with full-thickness or outer full-thickness stromal invasion following surgery had improved PFS when treated with SIB radiotherapy.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

Jason M. Broderick
October 21st 2025
Article

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

A Prescription Drug User Fee Act date of April 10, 2026, has been established by the FDA based on a Class II resubmission timeline.

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma

Tim Cortese
October 21st 2025
Article

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.